 |
| |
|
DNA Genetic Tests: Warfarin Dose Prediction
- Required only hours from blood sample to results
- Designed for easy operation & analysis
- Validated accuracy with 400+ patients samples* & DNA sequencing
- Protected by US, Europe, and world wide patents
- CE Marked IVD Kit Product Sheet <download - A4 / Letter>
Many studies have demonstrated the important role of genetic variability of vitamin K epoxide reductase (VKORC1) and cytochrome P450 2C9 (CYP2C9) genes in determining the dose of warfarin that should be used when the oral anticoagulant is initiated. Individuals that use DNA tests to determine their genotypes of these two genes can use the test results with other information to reach quickly a stable therapeutic dose while reducing drug adverse reactions at the same time. ( visit WarfarinDosing.org ) |
| |
Table : Warfarin Dosage Related SNP typing |
Genomic DNA |
Samples |
VKORC1
-1639(G>A) |
CYP2C9*3
c.1075(A>C) |
CYP2C9*2
c.430(C>T) |
Ethnicity of Health Volunteers |
|
GG |
GA |
AA |
AA |
AC |
CC |
CC |
CT |
TT |
Caucasian |
100 |
38 |
48 |
14 |
87 |
12 |
1 |
67 |
32 |
1 |
Han Chinese |
100 |
1 |
19 |
80 |
90 |
10 |
0 |
100 |
0 |
0 |
Asian |
246 |
35 |
78 |
133 |
231 |
14 |
1 |
242 |
4 |
0 |
Total |
446 |
74 |
145 |
227 |
408 |
36 |
2 |
409 |
36 |
1 |
|
| |
| VKORC1 (-1639 G>A) Test |
|
CYP2C9*2 (c.430 C>T) Test |
|
CYP2C9*3 (c.1075 A>C) Test |
| |
- VKORC1 TaqMan Detection Mix
- PCR Master Mix (2x conc.)
- Positive Control Templates
|
|
| |
Workflow |
|
| |
 |
|
| |
|
|
|
|
| |
- CYP2C9*2 TaqMan Detection Mix
- PCR Master Mix (2x conc.)
- Positive Control Templates
|
|
| |
Workflow |
|
| |
 |
|
| |
|
|
|
|
| |
- CYP2C9*3 TaqMan Detection Mix
- PCR Master Mix (2x conc.)
- Positive Control Templates
|
|
| |
Workflow |
|
| |
 |
|
| |
|
|
|
| |
|
|
|
|
|
| |
|
|
|
